Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 4 25 IN DEXTROSE 20 IN PLASTIC CONTAINER versus AMINOSYN II 8 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 4 25 IN DEXTROSE 20 IN PLASTIC CONTAINER versus AMINOSYN II 8 5.
AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER vs AMINOSYN II 8.5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn II 4.25% in Dextrose 20% provides amino acids for protein synthesis and dextrose as a caloric source. Amino acids are utilized for tissue repair and maintenance, while dextrose provides energy via glycolysis and oxidative phosphorylation.
Aminosyn II 8.5% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis when administered intravenously. It serves as a substrate for protein metabolism, promoting nitrogen retention and tissue repair.
Intravenous infusion of 500 mL to 1 L per day. Typical rate: 1-2 mL/min (60-120 mL/hr). Adjust based on caloric and fluid requirements.
Intravenous infusion, typical adult dose is 1.0 to 1.5 g amino acids/kg/day, administered as part of total parenteral nutrition; rate not to exceed 0.1 g amino acids/kg/hour.
None Documented
None Documented
Not applicable; components are endogenous substances. Clinical effect (nitrogen balance) persists 4-6 hours post-infusion.
Variable; individual amino acids have half-lives ranging from minutes to hours. Clinical context: infusion rate and metabolic demand determine steady-state levels.
Amino acids undergo metabolism; excess nitrogen is excreted renally as urea (80-90%), with minimal biliary/fecal elimination (<5%). Dextrose is metabolized.
Amino acids are primarily eliminated via metabolism; less than 10% is excreted renally as free amino acids. No significant biliary or fecal excretion.
Category C
Category C
Amino Acid Solution
Amino Acid Solution